ARTICLE | Clinical News
Krystexxa pegloticase regulatory update
July 1, 2013 7:00 AM UTC
The U.K.'s NICE issued final guidance recommending against the use of Krystexxa pegloticase from Savient to treat severe chronic tophaceous gout in adult patients - its approved indication. The guidan...